Home Newsfeeds Maxim Group Downgrades Kiora Pharmaceuticals to Hold

Maxim Group Downgrades Kiora Pharmaceuticals to Hold

Maxim Group analyst Michael Okunewitch downgrades Kiora Pharmaceuticals (NASDAQ:KPRX) from Buy to Hold.

byBenzinga Newsdesk

August 15, 2022

1 minute read

Maxim Group analyst Michael Okunewitch downgrades Kiora Pharmaceuticals (NASDAQ:KPRX) from Buy to Hold.

Apple’s AI Playbook: Why Tim Cook Is Not Following The Google And Microsoft Model

By Ananya Gairola

May 5, 12:53 AM

Amidst the aggressive pursuit of artificial intelligence by tech giants Microsoft Corporation (NASDAQ:MSFT) and Alphabet Inc. (NASDAQ:GOOG) (NASDAQ:GOOGL), Tim Cook says Apple Inc. (NASDAQ:AAPL) will tread thoughtfully. What…

AAPL

Citigroup Maintains Buy on DraftKings, Lowers Price Target to $20

By Benzinga Newsdesk

July 7, 7:28 AM

Citigroup analyst Jason Bazinet maintains DraftKings (NASDAQ:DKNG) with a Buy and lowers the price target from $26 to $20.

DKNG

On Dec 6, 2022, Penn Entertainment Board Authorized A New $750M Share Repurchase Program; New Authorization Expires On December 31, 2025

By Benzinga Newsdesk

December 8, 5:42 PM

On December 6, 2022, the Board of Directors of PENN Entertainment, Inc. (the "Company") authorized a new $750 million share repurchase program. The new authorization expires on December 31, 2025 and is in addition to the Company's existing $750 million share repurchase program authorized on February 1, 2022 ("February 2022 Authorization").

PENN